NCT05858177View on ClinicalTrials.gov

The Efficacy and Safety of Temozolomide in Patients With MPPGL

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

October 1, 2022

Study Completion Date

January 1, 2023

Conditions
Pheochromocytoma, MetastaticParaganglioma, MalignantPheochromocytoma Malignant
Interventions
DRUG

Temozolomide capsule

Temozolomide was given orally per day for 5 days, every 28 days until disease progression or intolerable toxicities.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT05858177 - The Efficacy and Safety of Temozolomide in Patients With MPPGL | Biotech Hunter | Biotech Hunter